Dimensional Fund Advisors LP Chinook Therapeutics, Inc. Transaction History

Dimensional Fund Advisors LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 09, 2023	BUY	$18.66 - $38.58 $978,026 - $2.02 Million	52,413 Added 4.08%	1,336,934 $51.4 Million
Q1 2023 May 12, 2023	BUY	$21.53 - $26.8 $999,874 - $1.24 Million	46,441 Added 3.75%	1,284,521 $29.7 Million
Q4 2022 Feb 09, 2023	BUY	$18.63 - $27.35 $2.32 Million - $3.4 Million	124,336 Added 11.16%	1,238,080 $32.4 Million
Q3 2022 Nov 10, 2022	BUY	$17.51 - $23.37 $4.93 Million - $6.57 Million	281,338 Added 33.8%	1,113,744 $21.9 Million
Q2 2022 Aug 12, 2022	BUY	$12.59 - $18.8 $3.93 Million - $5.86 Million	311,931 Added 59.93%	832,406 $14.6 Million
Q1 2022 May 13, 2022	BUY	$12.02 - $16.69 $2.75 Million - $3.82 Million	228,640 Added 78.35%	520,475 $8.52 Million
Q4 2021 Feb 09, 2022	BUY	$10.69 - $16.83 $919,895 - $1.45 Million	86,052 Added 41.82%	291,835 $4.76 Million
Q3 2021 Nov 12, 2021	BUY	$11.5 - $14.86 $1.26 Million - $1.62 Million	109,177 Added 113.01%	205,783 $2.63 Million
Q2 2021 Aug 12, 2021	BUY	$13.6 - $18.98 $1.13 Million - $1.58 Million	83,302 Added 626.14%	96,606 $1.36 Million
Q1 2021 May 14, 2021	SELL	$14.17 - $19.11 $997,482 - $1.35 Million	-70,394 Reduced 84.1%	13,304 $207,000
Q4 2020 Feb 25, 2021	BUY	$11.9 - $20.91 $996,006 - $1.75 Million	83,698 New	83,698 $1.33 Million

234K

Ticker KDNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,896,300
Description
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...

Get notified when there are updates to the investment portfolio of Dimensional Fund Advisors LP, based on Form 13F filings with the SEC.

Stay updated on Dimensional Fund Advisors LP with notifications on news.